TY - JOUR
T1 - Cost analysis and cost-effectiveness of open versus laparoscopic versus robot-assisted versus transanal total mesorectal excision in patients with rectal cancer
T2 - a protocol for a systematic review
AU - Geitenbeek, Ritchie T. J.
AU - Burghgraef, Thijs A.
AU - Broekman, Mark
AU - Schop, Bram P. A.
AU - Lieverse, Tom G. F.
AU - Hompes, Roel
AU - Havenga, Klaas
AU - Postma, Maarten
AU - Consten, Esther C. J.
N1 - Funding Information: EC is a proctor for Intuitive Surgical but no (financial) support from this organisation has been received for the submitted manuscript. Neither have there been any other activities or relations that could appear to have influenced the submitted work. All other authors declare: no support from any organisation for the submitted work; no financial relationships with organisations that may have an interest in the submitted work in the previous 3 years; and no other relationships or activities that could appear to have influenced the submitted work. Publisher Copyright: © BMJ Publishing Group Limited 2022.
PY - 2022/8/18
Y1 - 2022/8/18
N2 - INTRODUCTION: Nowadays, most rectal tumours are treated open or minimally invasive, using laparoscopic, robot-assisted or transanal total mesorectal excision. However, insight into the total costs of these techniques is limited. Since all three techniques are currently being performed, including cost considerations in the choice of treatment technique may significantly impact future healthcare costs. Therefore, this systematic review aims to provide an overview of evidence regarding costs in patients with rectal cancer following open, laparoscopic, robot-assisted and transanal total mesorectal excision. METHODS AND ANALYSIS: A systematic search will be conducted for papers between January 2000 and March 2022. Databases PubMed/MEDLINE, EMBASE, Scopus, Web of Science and Cochrane Library databases will be searched. Study selection, data extraction and quality assessment will be performed independently by four reviewers and discrepancies will be resolved through discussion. The Consensus Health Economic Criteria list will be used for assessing risk of bias. Total costs of the different techniques, consisting of but not limited to, theatre, in-hospital and postoperative costs, will be the primary outcome. ETHICS AND DISSEMINATION: No ethical approval is required, as there is no collection of patient data at an individual level. Findings will be disseminated widely, through peer-reviewed publication and presentation at relevant national and international conferences. TRIAL REGISTRATION NUMBER: CRD42021261125.
AB - INTRODUCTION: Nowadays, most rectal tumours are treated open or minimally invasive, using laparoscopic, robot-assisted or transanal total mesorectal excision. However, insight into the total costs of these techniques is limited. Since all three techniques are currently being performed, including cost considerations in the choice of treatment technique may significantly impact future healthcare costs. Therefore, this systematic review aims to provide an overview of evidence regarding costs in patients with rectal cancer following open, laparoscopic, robot-assisted and transanal total mesorectal excision. METHODS AND ANALYSIS: A systematic search will be conducted for papers between January 2000 and March 2022. Databases PubMed/MEDLINE, EMBASE, Scopus, Web of Science and Cochrane Library databases will be searched. Study selection, data extraction and quality assessment will be performed independently by four reviewers and discrepancies will be resolved through discussion. The Consensus Health Economic Criteria list will be used for assessing risk of bias. Total costs of the different techniques, consisting of but not limited to, theatre, in-hospital and postoperative costs, will be the primary outcome. ETHICS AND DISSEMINATION: No ethical approval is required, as there is no collection of patient data at an individual level. Findings will be disseminated widely, through peer-reviewed publication and presentation at relevant national and international conferences. TRIAL REGISTRATION NUMBER: CRD42021261125.
KW - colorectal surgery
KW - health economics
KW - oncology
UR - http://www.scopus.com/inward/record.url?scp=85136151039&partnerID=8YFLogxK
U2 - https://doi.org/10.1136/bmjopen-2021-057803
DO - https://doi.org/10.1136/bmjopen-2021-057803
M3 - Review article
C2 - 35981773
SN - 2044-6055
VL - 12
SP - e057803
JO - BMJ Open
JF - BMJ Open
IS - 8
M1 - e057803
ER -